Skip to content
Perifosine
Perifosine is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
42 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple myelomaD009101C90.02214
Colorectal neoplasmsD01517911
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C8092112
Kidney neoplasmsD007680EFO_0003865C64213
GliomaD005910EFO_0000520223
SarcomaD012509213
Colonic neoplasmsD003110C18112
Gastrointestinal stromal tumorsD046152EFO_0000505C49.A112
Brain neoplasmsD001932EFO_0003833C71112
GlioblastomaD005909EFO_0000515212
AstrocytomaD001254EFO_0000271212
OligodendrogliomaD009837EFO_0000631212
Show 15 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myelodysplastic syndromesD009190D4622
Ovarian neoplasmsD010051EFO_0003893C5611
Myeloid leukemia acuteD015470C92.011
Promyelocytic leukemia acuteD015473C92.411
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.011
Biphenotypic leukemia acuteD015456C95.011
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_000034011
Megakaryoblastic leukemia acuteD007947C94.211
Monocytic leukemia acuteD00794811
Myelomonocytic leukemia acuteD015479C92.511
Show 3 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePERIFOSINE
INNperifosine
Description
Perifosine is a phospholipid consisting of 1,1-dimethylpiperidinium-4-yl hydrogen phosphate in which the hydrogen is replaced by a stearyl (octadecyl) group. It has a role as an EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor. It is a phospholipid and an ammonium betaine. It is functionally related to an octadecan-1-ol.
Classification
Small molecule
Drug classphosphoro-derivatives; cytostatic phospholipid derivatives
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](C)(C)CC1
Identifiers
PDB
CAS-ID157716-52-4
RxCUI
ChEMBL IDCHEMBL372764
ChEBI ID67272
PubChem CID148177
DrugBankDB06641
UNII ID2GWV496552 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,244 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
16 adverse events reported
View more details